Neuroendocrine Tumor
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Neuroendocrine Tumor

What is the definition of Neuroendocrine Tumor?
Neuroendocrine tumors are rare cancers that grow from neuroendocrine cells. Neuroendocrine cells receive signals from the nervous system to release hormones. There are several types of neuroendocrine tumors, although most occur in the lungs, pancreas, adrenal glands, small intestine, appendix, and rectum. Neuroendocrine tumors may also spread to the lymph nodes, liver, or bones.
What are the symptoms of Neuroendocrine Tumor?
Symptoms of a neuroendocrine tumor depend on the tumor’s location and whether it is producing excess hormones. Symptoms of neuroendocrine tumors may include pain, a lump under the skin, fatigue, persistent cough or hoarseness, unexplained weight loss, confusion, anxiety, dizziness, shakiness, elevated blood glucose, low blood glucose, an ulcer, skin flushing, skin rash, increased thirst, nausea and vomiting, diarrhea, and carcinoid syndrome. Carcinoid syndrome is a condition that occurs when a neuroendocrine tumor produces excess hormones. Symptoms of carcinoid syndrome include skin flushing of the head and neck; sweating; shortness of breath; wheezing; rapid heartbeat; heart murmur; high blood pressure; yellowing of the skin and eyes; abdominal cramping; diarrhea; greasy, foul-smelling bowel movements; and swelling of the feet and legs.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Neuroendocrine Tumor?
Treatment for neuroendocrine tumors depends on the type and location, as well as whether the tumor is producing excess hormones. Treatment for endocrine tumors may include surgery; chemotherapy; targeted drug therapy, such as everolimus and sunitinib; immunotherapy, such as interferon alfa-2b; peptide receptor radionuclide therapy; somatostatin analogs, such as octreotide and lanreotide; radiation therapy; radiofrequency ablation; and hepatic artery embolization.
Who are the top Neuroendocrine Tumor Local Doctors?
Elite in Neuroendocrine Tumor
Hematology Oncology | Hematology | Oncology
Elite in Neuroendocrine Tumor
Hematology Oncology | Hematology | Oncology
Referral may be required

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
Languages Spoken:
English
Offers Telehealth

Diane Reidy is a Hematologist Oncology specialist and a Hematologist practicing medicine in Durham, North Carolina. Dr. Reidy is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.

Elite in Neuroendocrine Tumor
Surgical Oncology
Elite in Neuroendocrine Tumor
Surgical Oncology
Referral may be required
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Experience:
26+ years
Languages Spoken:
English
Offers Telehealth

Shishir Maithel is a Surgical Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 26 years. Dr. Maithel is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Gallbladder Disease, Pancreaticoduodenectomy, and Hepatectomy. Dr. Maithel is board certified in American Board Of Surgery - Surgery (Certified).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neuroendocrine Tumor
Endocrinology | Internal Medicine
Elite in Neuroendocrine Tumor
Endocrinology | Internal Medicine
Referral required

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception A, 
Ann Arbor, MI 
Languages Spoken:
English
Offers Telehealth

Dr. Else’s primary appointment is with the Division of Metabolism, Endocrinology and Diabetes. He received his MD degree from the University of Hamburg, Germany. He pursued his clinical training at the University of Hamburg (Residency: Internal Medicine) and the University of Michigan (Residency: Internal Medicine, Fellowship: Endocrinology). His main research interests are the genetics of endocrine tumors. Dr. Else’s clinical practice focuses on the care for patients with benign and malignant endocrine tumors, particularly pheochromocytoma, adrenocortical tumors and neuroendocrine tumors as well as accompanying hormone excess syndromes (e.g Cushing syndrome, primary aldosteronism). Dr. Else has a particular interest in taking care of patients with hereditary syndromes that predispose to the development of endocrine tumors (e.g. Multiple Endocrine Neoplasia (MEN) type 1, MEN2A & MEN2B, Hereditary Paraganglioma Syndrome). He attends the Multidisciplinary Endocrine Oncology Clinic, where patients with tumors receive diagnostic procedures and treatment. In addition he is part of the Cancer Genetics Clinic, which evaluates patients for hereditary syndromes and also facilitates regular exams and surveillance for patients at risk for endocrine tumors. Dr. Else is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. He is also highly rated in 105 other conditions, according to our data. His clinical expertise encompasses Adrenal Cancer, Adrenocortical Carcinoma, Adrenal Gland Adenoma, Neuroendocrine Tumor, and Thyroidectomy. Dr. Else is board certified in Internal Medicine and Endocrinology, Diabetes & Metabolism.

What are the latest Neuroendocrine Tumor Clinical Trials?
NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours

Summary: This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have previously received 177Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumor (GEPNET) that has spread from where it first started (primary site) to other places in the body (...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

Summary: This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions. Individuals \>=4 weeks with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participants will: * Fill out one or two questionnaires about their personal and family medical history. * Pro...